Targeted drug combo aims to shrink Hard-to-Treat head and neck tumors
NCT ID NCT07683507
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests a new drug, becotatug vedotin, combined with an immunotherapy (PD-1 inhibitor) in adults with advanced head and neck squamous cell carcinoma that cannot be surgically removed. The drug targets a protein called EGFR on cancer cells and delivers a toxin directly to them. The trial includes two groups: people who have not had prior treatment for advanced disease and those who have received at least one prior therapy. The main goal is to see how many participants' tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- becotatug vedotin combined with a PD-1 inhibitor
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced head and neck cancer, potentially shrinking tumors and delaying progression.
- What could go wrong
- This is an early-phase, single-arm study with only 60 participants. The drug may cause side effects, and results may not confirm benefit in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a short course of immunotherapy and radiation shrink head and neck tumors before surgery?
- Can a Two-Drug attack shrink Hard-to-Treat head and neck tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- Could a cheaper copy of keytruda work just as well against cancer?
- Smart T-Cell engager aims to outsmart tumors in first human test